90 results match your criteria: "and Department of Rheumatology and Clinical Immunology[Affiliation]"

Identification of a Therapeutic Window for Neurovascular Unit Repair after Experimental Spinal Cord Injury.

J Neurotrauma

November 2024

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Traumatic spinal cord injury (SCI) is a devastating condition for which effective neuroregenerative and neuroreparative strategies are lacking. The post-traumatic disruption of the blood-spinal cord barrier (BSCB) as part of the neurovascular unit (NVU) is one major factor in the complex pathophysiology of SCI, which is associated with edema, inflammation, and cell death in the penumbra regions of the spinal cord adjacent to the lesion epicenter. Thus, the preservation of an intact NVU and vascular integrity to facilitate the regenerative capacity following SCI is a desirable therapeutic target.

View Article and Find Full Text PDF

Hypovascular insulinoma with reduced microvessel density on histopathology: a case report.

Diabetol Int

October 2024

Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194 Japan.

Article Synopsis
  • A 41-year-old man suspected of having insulinoma underwent various imaging tests, revealing a hypovascular tumor in the pancreas, which was ultimately diagnosed as a Grade 1 PanNET following surgery and pathology.
  • The tumor's low microvessel density (MVD) of 3.9% contributed to inconclusive imaging results, highlighting the need for thorough preoperative evaluations in cases of hypovascular PanNETs to ensure accurate diagnosis and treatment.
View Article and Find Full Text PDF
Article Synopsis
  • The SIMPLIFY Japan study examined the transition from multiple daily insulin injections to once-daily iGlarLixi in adults with moderately controlled type 2 diabetes (T2D).
  • Over 24 weeks, participants showed significant improvements in health-related quality of life (HRQOL) scores, particularly in areas related to daily activities and treatment satisfaction, with minimal negative impact on glycemic control.
  • Additionally, there was an increase in treatment adherence and a small weight reduction, but incidences of hypoglycemia and gastrointestinal side effects were noted among participants.
View Article and Find Full Text PDF

Aims/introduction: PIONEER REAL Japan was a non-interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.

Materials And Methods: Adults naïve to injectable glucose-lowering therapies initiated oral semaglutide in routine clinical practice and were followed for 34-44 weeks. The primary endpoint was change in glycated hemoglobin (HbA) from baseline to end of study; the co-primary endpoint was number of adverse events (AEs).

View Article and Find Full Text PDF

Aims/introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety. We therefore carried out a large-scale, non-commercial, investigator-initiated study on the safety and effectiveness of the SGLT2 inhibitor tofogliflozin.

View Article and Find Full Text PDF
Article Synopsis
  • The Japan Diabetes Society (JDS) has formed a committee to regularly update consensus statements on diabetes management, starting with guidelines on "Medical Nutrition Therapy" in 2020, and a pharmacotherapy algorithm for type 2 diabetes in 2022.
  • The pharmacotherapy algorithm emphasizes tailoring medication choices to individual patients' diabetes pathology while also considering clinical evidence and prescribing practices in Japan.
  • Recent revisions to these consensus statements include the addition of tirzepatide—approved in April 2023—as a treatment option, alongside detailed assessments for insulin resistance based on new criteria for management.
View Article and Find Full Text PDF

A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms.

Diabetol Int

July 2024

Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School, 1-1 Yanagido, Gifu, 501-1194 Japan.

Unlabelled: Insulinomas can present with neuroglycopenic symptoms suggesting neuropsychiatric disorders, delaying diagnosis and treatment. We recently treated a 65-year-old woman with insulinoma who was misdiagnosed at her nearby psychiatric clinic as having schizophrenia because of personality changes and memory impairment; she was treated with brexpiprazole, which was discontinued due to persistence of the symptoms. Despite her relatively low casual plasma glucose (70 mg/dL), the physician at the psychiatric clinic did not investigate the possibility of hypoglycemia, partly because her HbA1c level (5.

View Article and Find Full Text PDF

Young-GRAPPA 2023: The Future Is Bright.

J Rheumatol

October 2024

F. Proft, MD, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany;

Two years after its inception, Young Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (Y-GRAPPA) has established itself as a productive network for junior investigators and clinicians. The group's achievements in the last year include updating the educational GRAPPA slide library, the "Bring a Derm" campaign to expand the GRAPPA community to include more dermatologists, and the publication of multiple "Do Not Miss" newsletters covering the highlights on PsDs from the major international conferences (American Academy of Dermatology [AAD] Annual Meeting, European Alliance of Associations for Rheumatology [EULAR] Congress, European Academy of Dermatology and Venereology [EADV] Congress, and American College of Rheumatology [ACR] Convergence).

View Article and Find Full Text PDF
Article Synopsis
  • - This algorithm outlines guidelines for the safe and effective use of medications to treat type 2 diabetes in Japan.
  • - Revisions emphasize the importance of considering safety issues and fatty liver disease as a related health concern.
  • - The updated guidelines also highlight the role of tirzepatide in the treatment options for this condition.
View Article and Find Full Text PDF

Aims/introduction: PIONEER REAL Japan was a non-interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes in routine clinical practice. We report baseline characteristics of participants enrolled in this study.

Materials And Methods: Adults aged ≥20 years with type 2 diabetes but no previous treatment with injectable glucose-lowering medication were enrolled.

View Article and Find Full Text PDF

Aldosterone secretion in primary aldosteronism (PA) is often regulated by adrenocorticotropic hormone (ACTH) in addition to its autonomous secretion. However, the clinical characteristics and risk of cardiovascular and cerebrovascular (CCV) events in PA patients with aldosterone responsiveness to ACTH stimulation remain unclear. This study aimed to investigate the prevalence of CCV events in PA patients with high aldosterone responsiveness to ACTH stimulation.

View Article and Find Full Text PDF
Article Synopsis
  • The SPARTA Japan study confirmed that the combination of insulin glargine and lixisenatide (iGlarLixi) is effective and safe for treating type 2 diabetes in Japanese adults over six months.
  • A post hoc analysis of the study looked at participant characteristics to see how these affected the achievement of glycemic targets based on age.
  • Results showed that older individuals with lower baseline HbA1c levels were more likely to achieve their glycemic targets, with greater reductions in HbA1c and body weight seen in the achieved group compared to the not-achieved group.
View Article and Find Full Text PDF

Visceral Adipose Tissue Quality and its Impact on Metabolic Health.

J Clin Endocrinol Metab

July 2024

Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.

View Article and Find Full Text PDF

The report by Adriaenssens et al. in JCI Insight 22 May 2023 explored the role and property of the neurons that express glucose-dependent insulinotropic polypeptide receptor (GIPR) in the brainstem and hypothalamus. The chemogenetic activation of the brainstem GIPR neurons and that of the hypothalamic GIPR neurons showed different feeding and behavior responses.

View Article and Find Full Text PDF

Background: The present study investigated lifestyle risk factors from metabolic syndrome-related lifestyles for a rapid decline in the estimated glomerular filtration rate (eGFR) among adults aged 40-74 years with treated and untreated type 2 diabetes.

Methods And Results: This study analyzed data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, encompassing the period from fiscal year (FY) 2017 to FY2020. We established FY2018 as our baseline year.

View Article and Find Full Text PDF

The diagnostic power of salivary electrolytes for Sjögren's disease: a systematic literature review and meta-analysis.

Clin Exp Rheumatol

December 2023

Department of Rheumatology and Clinical Immunology, University Medical Centre Groningen, University of Groningen, The Netherlands.

Objectives: To perform a systematic review and meta-analysis to determine the power of salivary electrolytes for the diagnosis of Sjögren's disease (SjD).

Methods: A literature search was conducted (last search March 2023) using PubMed and Web of Science and completed with a manual search. Articles were screened for reports of human salivary ion concentrations, comparing SjD patients with healthy controls and/or sicca patients.

View Article and Find Full Text PDF

Long-term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes.

J Diabetes Investig

January 2024

Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown in cardiovascular outcome trials to reduce the risk of heart failure and major adverse cardiovascular as well as renal events in individuals with type 2 diabetes. Moreover, clinical evidence indicates that SGLT2i use reduces heart failure and chronic kidney disease (CKD) in east Asian patients with type 2 diabetes. Thus, SGLT2is might seem to be the preferred treatment for older patients with type 2 diabetes even in the presence of multiple comorbidities.

View Article and Find Full Text PDF
Article Synopsis
  • The text addresses a correction concerning an academic article identified by its DOI (Digital Object Identifier) 10.1007/s13340-022-00605-x.
  • It suggests that there were errors or inaccuracies in the original publication that needed to be rectified.
  • The correction aims to ensure the integrity and accuracy of the research presented in the article for future reference.
View Article and Find Full Text PDF

Aim: Use of sodium-glucose co-transporter-2 inhibitors (SGLT2is) for glycaemic control is increasing in individuals with type 2 diabetes (T2D) for their additional benefits on heart failure and chronic kidney disease. However, SGLT2is generally reduce body weight, which might promote sarcopenia in older individuals. We evaluated the effects of the SGLT2i empagliflozin on muscle mass and strength in addition to glucose control in elderly adults with T2D.

View Article and Find Full Text PDF

Unmasked insulinoma occasioned by severe hypoglycemic coma immediately postpartum: a case report.

BMC Endocr Disord

August 2023

Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Article Synopsis
  • Insulinomas are rare in pregnant women, with most cases diagnosed early in pregnancy or right after delivery; this case involved a patient who experienced severe hypoglycemic coma postpartum, prompting further investigation.
  • Initially, her hypoglycemia was misattributed to hyperemesis gravidarum, but after recurrent episodes post-delivery, tests revealed an insulin-secreting tumor in the pancreas.
  • Successful treatment included a spleen-preserving distal pancreatectomy, highlighting the importance of monitoring for insulinoma in pregnant women experiencing severe hypoglycemia.
View Article and Find Full Text PDF

Sex Differences in Clinical Manifestations of Hospitalized Patients With Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Cohort Study.

J Rheumatol

October 2023

M. Li, MD, X. Tian, MD, X. Zeng, MD, L. Wang, MD, F. Zhang, MD, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing;

Objective: To investigate the effect of sex on the clinical characteristics, prognoses, and therapeutic selection of eosinophilic granulomatosis with polyangiitis (EGPA).

Methods: We retrospectively enrolled 170 hospitalized patients with EGPA who were managed at our hospital between 2007 and 2020. Detailed clinical data were reviewed.

View Article and Find Full Text PDF

Objectives: To determine the spectrum of anti-neutrophil cytoplasmic antibody (ANCA) antigen-specificities in eosinophilic granulomatosis with polyangiitis (EGPA), an ANCA-associated vasculitis (AAV) entity.

Methods: We conducted a retrospective analysis of 73 EGPA patients from three German tertiary referral centres for vasculitis. In addition to in-house ANCA testing, pentraxin 3 (PTX3)- and olfactomedin 4 (OLM4)-ANCA were determined using a prototype cell-based assay for research (EUROIMMUN, Lübeck, Germany).

View Article and Find Full Text PDF

Aims/introduction: We aimed to clarify the effectiveness of the Diabetic Nephropathy Aggravation Prevention Program in Japan by comparing the diabetes-related medical visit behavior of individuals under the municipal national health insurance according to insurers' effort levels.

Materials And Methods: We assessed changes in medical visit behavior according to insurers' effort levels, "Full Efforts," "Some Efforts" and "No Effort," using longitudinal data from the National Database of Health Insurance Claims and Specific Health Checkups before 2015 and after 2018 regarding the national health insurance programs in Japan. We analyzed the effect of the Diabetic Nephropathy Aggravation Prevention Program using a generalized linear mixed model for 208,388 participants with diabetes.

View Article and Find Full Text PDF

Background: Drug-induced hypocarnitinemia has been noted as a cause of hypoglycemia in children. However, adult cases are extremely rare and pre-existing conditions (including endocrine disorders and frailty) have been suggested to be involved. Hypoglycemia due to drug-induced hypocarnitinemia is quite rare, and there were few reports of pivoxil-containing cephalosporin (PCC)-induced hypocarnitinemia in adults.

View Article and Find Full Text PDF

Introduction: iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, is one option for treatment intensification in individuals with type 2 diabetes (T2D) who are unable to achieve targeted glycaemic control with their current glucose-lowering agent. Real-world data on the impact of prior treatment on the effectiveness and safety of iGlarLixi may be useful to guide individualised treatment decisions.

Methods: This analysis of the 6-month, retrospective, observational SPARTA Japan study compared glycated haemoglobin (HbA1c), body weight and safety for pre-specified subgroups defined by prior treatment: post oral antidiabetic agent (OAD), GLP-1 RA, basal insulin (BI) + OADs (BOT), GLP-1 RA + BI or multiple daily injections (MDI).

View Article and Find Full Text PDF